Hansen Pharmaceutical, LLC

Hansen Pharmaceutical seeks to treat and prevent infections caused by antibiotic-resistant bacteria. Hansen Pharmaceutical, LLC, is developing gaseous nitric oxide under pressure to improve patient quality of life by reducing infection rates and treating infections. By mitigating infection, Hansen hopes to lower the number of amputations and other serious medical procedures brought on by bacterial infection. Diabetic foot complications, including infection, are a tremendous societal burden, costing more than $17 billion annually and leading to over 80,000 lower extremity amputations in the United States per year. More money is spent on diabetic foot complications than on breast cancer treatment in the US. Combined with rising rates of diabetes, aging populations, increased antibiotic resistance, and ever-growing health care costs, simply treating infections effectively has never been more critical. Since spinning out the technology and intellectual property in 2017, Hansen is building on the groundbreaking work started at Barry University’s Paul & Margaret Brand Research Center at the School of Podiatric Medicine. Hansen’s core proprietary technology delivers gaseous nitric oxide under pressure (gNOp) to kill multi-drug resistant organisms such as MRSA, staphylococcus aureus, pseudomonas, and Acinetobacter baumannii. Hansen is developing the technology to drive nitric oxide into wounds to kill bacteria both on the surface and subcutaneously. According to the World Health Organization, antibiotic resistance leads to longer hospital stays, higher medical costs, and increased mortality. This is such a significant issue that the WHO has established the Global Antibiotic Research and Development Partnership to develop and deliver new treatments or improve existing treatments by 2023. Hansen is positioned to address this need.